Rheumatology Doctors in Columbia, MO Accepting Medicare

5 Rheumatology doctors found. Showing 1 - 5

Darcy D Folzenlogen, M.D. Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 1101 Hospital Drive, Columbia, MO 65212 Phone: 573-882-8788    Fax: 573-882-3131

Sara E Walker, MD Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: One Hospital Dr, Columbia, MO 65212 Phone: 573-882-8095    Fax: 573-882-1380

Paula Jean Mcmurtry, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 900 W Nifong Blvd Ste 101, Columbia, MO 65203 Phone: 573-815-6640    Fax: 573-815-6644

Anthony T Tay, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3610 Buttonwood Dr, Suite 200, Columbia, MO 65201 Phone: 417-689-4080

William L Washington, MD Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 3615 Augusta Dr, Columbia, MO 65203 Phone: 573-443-7780

News Archive

New report finds sharp increase in emergency department visits involving adverse reactions to zolpidem

A new report shows that the number of emergency department visits involving adverse reactions to the sleep medication zolpidem rose nearly 220 percent from 6,111 visits in 2005 to 19,487 visits in 2010.

Cephalon to acquire Gemin X Pharmaceuticals

Cephalon, Inc. announced today that it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis. Gemin X stockholders could also receive up to $300 million in cash payments upon the achievement of certain regulatory and sales milestones.

Public access policy for NIH-funded research set to become law

The U.S. Senate last night approved the FY2008 Labor, HHS, and Education Appropriations Bill (S.1710), including a provision that directs the National Institutes of Health (NIH) to strengthen its Public Access Policy by requiring rather than requesting participation by researchers.

Amgen expected to enter a guilty plea to unspecified charges

The biotech giant is expected to plead guilty in a New York federal court criminal case. Some reports suggest the charges relate to "misbranding" - which refers to the promotion of drugs for uses that have not gained the Food and Drug Administration's approval.

Read more Medical News

› Verified 1 days ago